- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01837667
Phase I Study of LB-100 With Docetaxel in Solid Tumors
A Phase I Study of Intravenous LB-100 for Injection as a Single Agent and in Combination With Docetaxel in the Treatment of Patients With Advanced Solid Tumors
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- City of Hope National Medical Center
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Nevada
-
Las Vegas, Nevada, United States, 89169
- Comprehensive Cancer Centers of Nevada
-
-
Texas
-
Dallas, Texas, United States, 75246
- Texas Oncology - Baylor Charles A. Sammons Cancer Center
-
Tyler, Texas, United States, 75702
- Texas Oncology - Tyler
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Part 1 only: Patients with histologically or cytologically proven progressive or metastatic solid tumors who have failed standard treatment and have no other effective treatment available.
Part 2 only: Patients with histologically or cytologically proven progressive or metastatic solid tumors who have failed standard treatment and have no other effective treatment available, or docetaxel-naive patients who have failed standard treatment and have tumors for which a docetaxel-based regimen would be appropriate.
- Part 2 only: Patients must be docetaxel-naive.
- Patients must have a life expectancy of at least 12 weeks.
- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Patients must be men and women >= 18 years of age.
- Patients must have recovered from all acute adverse effects (excluding alopecia) of prior therapies to baseline or <= grade 1 prior to study entry.
- Patients must have adequate bone marrow function, defined as an absolute neutrophil count >= 1.5 x 10^9/L and a platelet count >= 100 x 10^9/L.
- Patients must have adequate renal function, defined as serum creatinine <= 1.5 x upper limit of normal (ULN) for the institution or a calculated creatinine clearance [Cockcroft-Gault method] must be >= 60 mL/min/1.73 m^2).
Patients must have adequate hepatic function, defined as:
- Part 1 only: plasma total bilirubin <= 1.5 mg/dL, alanine transaminase (ALT) and aspartate transaminase (AST) <= 2.5 X ULN.
- Part 2 only: plasma total bilirubin <= ULN; ALT and/or AST <= 1.5 X ULN concomitant with alkaline phosphatase <= 2.5 X ULN.
- Female patients of childbearing potential must have a negative serum or urine pregnancy test result at time of pre-treatment screening.
- Patients with reproductive potential must agree to use at least one form of barrier contraception prior to study entry and for up to 30 days beyond the last administration of study drug.
- Patients must be capable of providing informed consent and must be willing to provide written informed consent prior to the start of any study-specific procedures.
Exclusion Criteria:
- Patients may not have had prior chemotherapy, radiotherapy, hormonal therapy, or biologic therapy in the 4 weeks prior to study entry with the exception of mitomycin C or nitrosoureas, for which patients must be 6 weeks from prior treatment. For patients who have been treated with targeted therapy, 5 half-lives of that therapy (or 28 days, whichever is shorter) must have passed prior to enrollment in the study.
- Part 2 only: Patients may not have had prior treatment with docetaxel.
- Part 2 only: Patients with plasma total bilirubin > ULN; ALT and/or AST > 1.5 X ULN concomitant with alkaline phosphatase > 2.5 X ULN.
Patients may not have any concomitant condition that could compromise the objectives of this study and the patients' compliance and ability to tolerate this therapy and complete at least 2 cycles of therapy, including, but not limited to the following:
- Congestive heart failure or uncontrolled angina pectoris, previous history of myocardial infarction within 1 year from study entry, uncontrolled hypertension, or dysrhythmias.
- Active infection.
- Unstable diabetes mellitus.
- Psychiatric disorder that may interfere with consent and/or protocol compliance.
- Uncontrolled seizure activity.
- Prior history of inflammatory bowel disease.
- Prior history of pulmonary fibrosis.
- Prior history of cardiomyopathy.
- Patients with a history of central nervous system (CNS) malignancy.
- Pregnant or breastfeeding women.
- Patients with another malignancy in the past 3 years except: curatively treated non-melanoma skin cancer, or carcinoma in situ (either cervix or breast) that does not require further treatment.
- Patients with known active human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection.
- Part 2 only: Patients with a history of severe hypersensitivity reaction to drugs formulated with polysorbate 80 (for example, drugs formulated with polysorbate 80 include, but are not limited to: Aranesp, Eprex, Cordarone, some vaccines).
- Part 2 only: Patients with >= grade 2 peripheral neuropathy.
- Patients with an underlying diagnosis or disease state associated with an increased risk of bleeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LB-100 for Injection and Docetaxel
Part 1: LB-100 infusion.
Part 2: LB-100 infusion and docetaxel infusion.
|
Part 1 and Part 2: LB-100 for Injection infusion on Days 1,2,3 of each 21 day cycle.
Part 2: Docetaxel infusion on Day 2 of each 21 day cycle.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of patients with adverse events as a measure of safety and tolerability of LB-100 for Injection treatment plus docetaxel.
Time Frame: Starting from date of first dose up to 30 days after last dose.
|
Starting from date of first dose up to 30 days after last dose.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Fadi Braiteh, MD, Comprehensive Cancer Centers of Nevada
- Principal Investigator: Aaron Mansfield, MD, Mayo Clinic
- Principal Investigator: Vincent Chung, MD, FACP, City of Hope National Medical Center
- Principal Investigator: Carlos Becerra, MD, Texas Oncology - Baylor Charles A Sammons Cancer Center
- Principal Investigator: Donald Richards, MD, Texas Oncology - Tyler
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- L12-20661
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms
-
GlaxoSmithKlineCompleted
-
Amphia HospitalRecruitingColonic Neoplasms MalignantNetherlands
-
Marquette General Health SystemUpper Michigan Brain Tumor CenterWithdrawnGlioma | MeningiomaUnited States
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedBrain Stem Neoplasms, Primary | Neoplasms, Brain StemUnited States
-
European Association for Endoscopic SurgeryWithdrawn
-
GlaxoSmithKlineRecruitingNeoplasms, RectalUnited States, France, Italy, Japan, Spain, United Kingdom, Germany, Korea, Republic of, Canada, Netherlands
-
Russian Society of Colorectal SurgeonsRecruitingNeoplasms,ColorectalRussian Federation
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
-
Novartis PharmaceuticalsBayerCompletedColorectal Neoplasms | Rectal Neoplasms | Colonic NeoplasmsUnited States, Germany, Belgium, Canada, Spain, United Kingdom, Taiwan, France, Switzerland, Sweden, Portugal, New Zealand, Italy, Slovakia, Australia, Austria, Brazil, Hong Kong
Clinical Trials on LB-100 for Injection
-
University of California, San DiegoCalifornia Institute for Regenerative Medicine (CIRM); Cystinosis Research...Active, not recruiting
-
The Netherlands Cancer InstituteNot yet recruitingMetastatic Microsatellite-stable Colorectal Cancer
-
Ain Shams UniversityCompleted
-
Almirall, S.A.Completed
-
National Cancer Institute (NCI)CompletedGlioma | Glioblastoma Multiforme | Giant Cell Glioblastoma | Oligodendrogliomas | Astrocytoma, Grades II, III and IVUnited States
-
Lixte Biotechnology Holdings, Inc.UnknownMyelodysplastic SyndromesUnited States
-
Juventas Therapeutics, Inc.UnknownIschemic Heart FailureUnited States
-
Guangdong GD Kongming Biotech LLCJinan University GuangzhouWithdrawnAdvanced Hepatocellular CarcinomaChina
-
M.D. Anderson Cancer CenterGSK Pharma; LixteRecruitingOvarian Clear Cell CarcinomaUnited States
-
Sotiria General HospitalUnknownSevere Eosinophilic AsthmaGreece